便通胶囊防治神经外科术后便秘的随机对照研究
|
摘要
目的:比较便通胶囊与麻仁润肠丸治疗神经外科术后便秘的临床疗效及安全性。方法:选取2014年1月至2016年12月西安交通大学第一附属医院由治的神经外科术后患者192例作为研究对象,采用随机对照设计,随机分为观察组和对照组,每组96例。观察组服用便通胶囊,3粒/次,2次/d;对照组服用麻仁润肠丸,1～2丸/次,2次/d。2组疗程均为2周。记录2组患者术后72 h便秘发生率,术后3 d引流量,住院时间与首次排便时间,术后第1、3、7天免疫功能水平变化,术后并发症及不良反应等。结果:观察组术后72 h便秘发生率为2. 01%,显著低于对照组的9. 38%,2组间比较差异有统计学意义(P <0. 05);术后第1天引流量组间比较,差异无统计学意义(P> 0. 05),但术后第2、3天观察组引流量均低于对照组,差异有统计学意义(P <0. 05)。观察组住院时间、置管时间与首次排便时间均短于对照组,各项指标组间差异有统计学意义(P <0. 05); 2组免疫功能变化情况、术后并发症和不良反应情况,观察组疗效均优于对照组,组间差异有统计学意义(P <0. 05)。结论:便通胶囊对神经外科术后便秘有显著治疗作用,对免疫功能有一定调节作用,疗效优于麻仁润肠丸,临床使用安全性高。
Objective: To compare the efficacy and safety of Bian Tong Capsule and Maren Runchang Pill in treating constipation after neurosurgery. Methods: A total of 192 patients undergoing neurosurgery in the First Affiliated Hospital of Xi'an Jiaotong University from January 2014 to December 2016 were enrolled in the randomized controlled trial. They were randomly divided into the observation group and the control group,with 96 in each group. The observation group took Biantong capsule,3 capsules a day,2 times a day for 2 weeks,and the control group took Maren Runchang Pills,1 to 2 pills a day,2 times a day,for 2 weeks. The incidence of constipation at 72 hours after operation,the drainage volume at 3 days postoperatively,the length of hospital stay and the first defecation time,the changes of immune function at the 1 st,3 rd,and 7 th postoperative days,and postoperative complications were recorded. Results: The incidence of constipation at the 72 h postoperatively was 2. 01% in the observation group,which was significantly lower than 9. 38% in the control group 9. 38%. The difference between the two groups was statistically significant( P < 0. 05). There was no difference in drainage volume between the 2 groups on the first day after operation( P > 0. 05),but the drainage volume of the observation group was lower than that of the control group on the second and third day after operation( P <0. 05). The hospitalization time,drainage tube indwelling time and the first defecation time were shorter in the observation group than in the control group. The difference between the groups was statistically significant( P < 0. 05); the change of immune function level and postoperative complications and the adverse reactions of the 2 groups were better than the control group. There were statistically significant differences between the groups( P < 0. 05). Conclusion: Biantong Capsule has significant therapeutic effects on constipation after neurosurgery,and has certain regulation effects on immune function. The curative effect is better than that of Maren Runchang Pill. It has high clinical safety and is worthy of clinical application.
Objective: To compare the efficacy and safety of Bian Tong Capsule and Maren Runchang Pill in treating constipation after neurosurgery. Methods: A total of 192 patients undergoing neurosurgery in the First Affiliated Hospital of Xi'an Jiaotong University from January 2014 to December 2016 were enrolled in the randomized controlled trial. They were randomly divided into the observation group and the control group,with 96 in each group. The observation group took Biantong capsule,3 capsules a day,2 times a day for 2 weeks,and the control group took Maren Runchang Pills,1 to 2 pills a day,2 times a day,for 2 weeks. The incidence of constipation at 72 hours after operation,the drainage volume at 3 days postoperatively,the length of hospital stay and the first defecation time,the changes of immune function at the 1 st,3 rd,and 7 th postoperative days,and postoperative complications were recorded. Results: The incidence of constipation at the 72 h postoperatively was 2. 01% in the observation group,which was significantly lower than 9. 38% in the control group 9. 38%. The difference between the two groups was statistically significant( P < 0. 05). There was no difference in drainage volume between the 2 groups on the first day after operation( P > 0. 05),but the drainage volume of the observation group was lower than that of the control group on the second and third day after operation( P <0. 05). The hospitalization time,drainage tube indwelling time and the first defecation time were shorter in the observation group than in the control group. The difference between the groups was statistically significant( P < 0. 05); the change of immune function level and postoperative complications and the adverse reactions of the 2 groups were better than the control group. There were statistically significant differences between the groups( P < 0. 05). Conclusion: Biantong Capsule has significant therapeutic effects on constipation after neurosurgery,and has certain regulation effects on immune function. The curative effect is better than that of Maren Runchang Pill. It has high clinical safety and is worthy of clinical application.
引文
[1]郝京京,武元星,王强.神经外科术后颅内感染的危险因素及降钙素原等炎性标志物的诊断价值[J].临床神经外科杂志,2016,13(5):348-351.
[2]姚喆,张晓峰,廖华山.右美托咪定复合丙泊酚对脑胶质瘤切除术中脑组织损伤的影响[J].海南医学院学报,2017,23(14):1910.
[3]尤梦洁,陈志.神经外科手术患者术后综合康复护理对策[J].The Medical Journal of the Present Clinical,2018,31(4):3997-4001.
[4]江基尧,朱诚.现代颅脑损伤学[M].上海:第二军医大学出版社,2004:134-140.
[5]王忠诚.神经外科学[M].武汉:湖北科学技术出版社,1998:335-337.
[6]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2014)[J].中华神经科杂志,2015,48(6):435-444.
[7]傅兰清,胡亚俊,翟莉.便通胶囊防治胸腰椎骨折术后便秘的随机对照研究[J].世界中医药,2017,12(3):576-578.
[8]刘婷,廖兴志,吴文华.右美托咪定联合丙泊酚麻醉对神经外科手术患者血流动力学及炎性因子水平的影响[J].湖南师范大学学报:医学版,2018,15(2):94-97.
[9]杨春霞,彭飞,梁燕霞.颅神经外科手术后引流管的观察与护理[J].中国伤残医学,2012,20(5):36-37.
[10]吴彬彬,陆艳,何蝉.颅脑损伤患者术后血清TNF-a,IL-6,Ig G,Ig M,C3水平的动态变化及其临床意义[J].临床神经外科杂志,2017(38)24:3413-3417.
[11]李颖棋,任华伟.细节护理对手术室护理质量的影响[J].齐鲁护理杂志,2016,22(10):84-85.
[12]吴春颖,曹文军,吕建华,等.颅脑损伤患者术后血清中细胞因子与体液免疫变化的临床意义[J].重庆医学,2016,45(5):577-579.
[13]王雪梅,万海霞.神经外科护理安全隐患分析及防范措施研究[J].护理实践与研究,2012,9(7):94-95.
[14]闰雨佳,胡思源,杨娜,等.欧洲药品管理局人用药品委员会治疗慢性便秘药物研发临床评价指南介绍[J].中国新药杂志,2015,24(16):1867-1869.
[15]肖飞,翟莉,唐庆,等.便通胶囊治疗慢性便秘的作用机制分析[J].世界中医药,2016,11(12):2802-2803.
[16]杨艳霞,翟莉,游冬阁,等.便通胶囊临床应用综述[J].世界中医药,2016,11(10):2197-2199.
[17]卜岚.便通胶囊治疗全子宫切除术后便秘的临床研究[J].世界中医药,2018,13(7):1662-1665.
[18]王磊,郭继中.六味安消胶囊联合枯草二联杆菌胶囊治疗便秘型肠易激综合征的疗效研究[J].中国医药,2012,7(1):60-62.
[19]赵先晓,陈向习,何秋琼,等.神经外科患者术后颅内感染的相关危险因素分析及其护理对策[J].中国临床新医学,2016,9(2):164-166.
[2]姚喆,张晓峰,廖华山.右美托咪定复合丙泊酚对脑胶质瘤切除术中脑组织损伤的影响[J].海南医学院学报,2017,23(14):1910.
[3]尤梦洁,陈志.神经外科手术患者术后综合康复护理对策[J].The Medical Journal of the Present Clinical,2018,31(4):3997-4001.
[4]江基尧,朱诚.现代颅脑损伤学[M].上海:第二军医大学出版社,2004:134-140.
[5]王忠诚.神经外科学[M].武汉:湖北科学技术出版社,1998:335-337.
[6]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2014)[J].中华神经科杂志,2015,48(6):435-444.
[7]傅兰清,胡亚俊,翟莉.便通胶囊防治胸腰椎骨折术后便秘的随机对照研究[J].世界中医药,2017,12(3):576-578.
[8]刘婷,廖兴志,吴文华.右美托咪定联合丙泊酚麻醉对神经外科手术患者血流动力学及炎性因子水平的影响[J].湖南师范大学学报:医学版,2018,15(2):94-97.
[9]杨春霞,彭飞,梁燕霞.颅神经外科手术后引流管的观察与护理[J].中国伤残医学,2012,20(5):36-37.
[10]吴彬彬,陆艳,何蝉.颅脑损伤患者术后血清TNF-a,IL-6,Ig G,Ig M,C3水平的动态变化及其临床意义[J].临床神经外科杂志,2017(38)24:3413-3417.
[11]李颖棋,任华伟.细节护理对手术室护理质量的影响[J].齐鲁护理杂志,2016,22(10):84-85.
[12]吴春颖,曹文军,吕建华,等.颅脑损伤患者术后血清中细胞因子与体液免疫变化的临床意义[J].重庆医学,2016,45(5):577-579.
[13]王雪梅,万海霞.神经外科护理安全隐患分析及防范措施研究[J].护理实践与研究,2012,9(7):94-95.
[14]闰雨佳,胡思源,杨娜,等.欧洲药品管理局人用药品委员会治疗慢性便秘药物研发临床评价指南介绍[J].中国新药杂志,2015,24(16):1867-1869.
[15]肖飞,翟莉,唐庆,等.便通胶囊治疗慢性便秘的作用机制分析[J].世界中医药,2016,11(12):2802-2803.
[16]杨艳霞,翟莉,游冬阁,等.便通胶囊临床应用综述[J].世界中医药,2016,11(10):2197-2199.
[17]卜岚.便通胶囊治疗全子宫切除术后便秘的临床研究[J].世界中医药,2018,13(7):1662-1665.
[18]王磊,郭继中.六味安消胶囊联合枯草二联杆菌胶囊治疗便秘型肠易激综合征的疗效研究[J].中国医药,2012,7(1):60-62.
[19]赵先晓,陈向习,何秋琼,等.神经外科患者术后颅内感染的相关危险因素分析及其护理对策[J].中国临床新医学,2016,9(2):164-166.